Drug intelligence / Profile preview

HSVTI Formulation 2

Development stage: Phase 2
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics

Overview

HSVTI Formulation 2 is part of an investigational vaccine candidate for Herpes Simplex Virus (HSV). It is being studied in a clinical trial to evaluate its safety, immune response, and efficacy. The trial involves administering two doses of the formulation to participants. The exact mechanism of action is not detailed, but it is part of a broader effort to develop immunotherapies against HSV.

Other names: HSVTI_F2

Targets

gD (HSV-2 glycoprotein D)

Beyond the preview

Go deeper on HSVTI Formulation 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HSVTI Formulation 2.

Explore the full profile